Liver Diseases Clinical Trial
Official title:
Expanded Criteria Donors in Liver and Kidney Transplantation: Protocol of a Randomised Single Center Clinical Trial of Hypothermic Oxygenated Perfusion Versus Static Cold Storage
With the present study the investigators will evaluate the benefit of end-ischemic HOPE on ECD grafts (livers and kidneys) as compared to SCS. Organs will be perfused through a recently developed machine perfusion (MP) device, from the beginning of back-table procedures till implantation, without increasing CIT. The aim of the study will be demonstrating the ability of HOPE to improve graft function and post-operative outcomes of ECD kidney and liver recipients.
Extended criteria donors (ECD) are widely utilized due to organ shortage, but this may
increase the risk of graft dysfunction and of poorer outcomes.
Hypothermic oxygenated perfusion (HOPE) is a recent organ preservation strategy for marginal
kidney and liver grafts, which allows to redirect anaerobic metabolism to aerobic metabolism
under hypothermic conditions and to protect grafts from oxidative species-related damage;
these mechanisms may potentially improve graft function and survival.
Methods This is an open-label, randomized multicenter clinical trial with the aim of
comparing HOPE vs. static cold storage (SCS) in ECD kidney and liver transplantation.
In the study protocol - approved by ethics committee - 220 patients (110 liver recipients and
110 kidney recipients) will be enrolled. Livers and kidneys assigned to HOPE will be perfused
by machine perfusion with cold Belzer solution (4°-10°C) and with continuous oxygenation
(partial pressure of oxygen = 500-600 mmHg). In the control group, livers and kidneys
undergoing SCS will be steeped in Celsior or University of Wisconsin Belzer solutions and
stored in ice. Using the same perfusion machine for both liver and kidney grafts, organs will
be perfused from the start of the back-table procedure until implantation, without increasing
cold ischemia time (CIT). For each group the investigators will evaluate clinical outcomes,
graft function tests and histologic findings, as well as perfusate and the number of
allocated organs.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05255042 -
Tissue Models for Liver Disease
|
||
Completed |
NCT04473482 -
Michigan Alcohol Improvement Network- Alcohol Reduction and Treatment Trial
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT02917408 -
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
|
||
Recruiting |
NCT03773887 -
Comparison of Inflammatory Profiles and Regenerative Potential in Alcoholic Liver Disease
|
N/A | |
Recruiting |
NCT00345930 -
DILIN - Prospective Study
|
||
Completed |
NCT00148031 -
Improving Hepatitis C Treatment in Injection Drug Users
|
Phase 4 | |
Terminated |
NCT00031135 -
Total Parenteral Nutrition-Associated Liver Disease
|
Phase 2 | |
Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
Completed |
NCT00222664 -
Qidong Hepatitis B Intervention Study
|
Phase 4 | |
Recruiting |
NCT06195917 -
Robotic-assisted Percutaneous Transhepatic Puncture
|
N/A | |
Recruiting |
NCT04551742 -
Social & Contextual Impact on Children Undergoing Liver Transplantation
|
||
Completed |
NCT04782050 -
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Recruiting |
NCT04518852 -
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
|
Phase 2 | |
Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
Terminated |
NCT03396705 -
Liver Regeneration
|
||
Completed |
NCT04341012 -
Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases
|
||
Recruiting |
NCT05733832 -
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
|
N/A |